Discontinuing semaglutide typically results in gradual weight regain as appetite dysregulation returns
Fudim M, White J, Pagidipati NJ, Lokhnygina Y, Wainstein J, Murin J, Iqbal N, Ohman P, Lopes RD, Reicher B, Holman RR, Hernandez AF, Mentz RJ
MASLD develops over several years
The cardiovascular benefits of GLP-1s may be independent of improvements in glycemic control, and in part be driven by reductions in inflammation and cytokine response driving plaque formation in the arterial wall
Weekly Injection: Many people find a "one-and-done" weekly injection more convenient than remembering a daily medication
Potential Research-Observed Benefits Clinical studies have observed associations between retatrutide use and changes in appetite regulation and glycemic markers within controlled research settings